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background:  Bivalirudin compared with heparin has been shown to reduce rates of bleeding and death in patients undergoing primary 
percutaneous coronary intervention (PCI). In light of recent evidence, this study compares the acute outcomes and cost in a contemporary 
population of patients with ST elevation myocardial infarction (STEMI) undergoing PCI.
methods:  CathPCI Registry prospective data from 1/1/11 till 3/31/13 at 2 tertiary care centers in the New York area was obtained. 
Univariate, bivariate and propensity score adjusted analyses were performed. The primary endpoint was acute adverse outcome 
(composite of bleeding and transfusion). The secondary one was cost effectiveness.
Results:  Among the 795 STEMI patients undergoing PCI (605 Bivalirudin) heparin monotherapy patients were younger, more often 
diabetic and with higher use of transradial approach. There were no statistically significant differences in outcomes (composite and 
individual) between heparin and bivalirudin (OR 1.03, p=0.935; OR 0.90, p=0.837; OR 1.01, p=0.974 respectively), including after 
propensity score adjustment. A cost analysis showed a potential for a per annum cost reduction of USD 0.3M by replacing bivalirudin with 
heparin (Table).
conclusion:  There were no statistically significant differences in outcomes but a significant cost reduction in using heparin instead of 
bivalirudin in a STEMI population undergoing PCI. Further consideration should be given to a heparin monotherapy approach in these 
patients.
